Treatment of refractory anemias with methenolone.

Abstract

A therapeutic trial with methenolone (Primobolan) in 19 consecutive patients with different types of refractory anemia is reported. The remission frequencies were: pancytopenia 3/6, bicytopenia 2/4, refractory anemia with hyperplastic marrow 1/5, myelofibrosis 1/4. There was no obvious prolongation of survival in the patients responding. Side-effects were negligible.

• Authors: D Lockner
• Journal: Acta medica Scandinavica (Acta Med Scand) Vol. 205 Issue 1-2 Pg. 97-101 ( 1979) ISSN: 0001-6101 [Print] Sweden
• PMID: 367090 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Methenolone

Topics

• Aged
• Agranulocytosis (drug therapy)
• Anemia, Aplastic (drug therapy, mortality)
• Chemical and Drug Induced Liver Injury
• Clinical Trials as Topic
• Drug Evaluation
• Female
• Humans
• Liver (drug effects)
• Male
• Methenolone (adverse effects, therapeutic use)
• Middle Aged
• Pancytopenia (drug therapy)
• Primary Myelofibrosis (drug therapy)
• Remission, Spontaneous
• Virilism (chemically induced)